Allogene Therapeutics (ALLO) said Tuesday that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to its allogeneic CAR T candidate, ALLO-316, for treating adult patients with a type of advanced renal cell carcinoma.
The designation follows data from a phase 1 trial showing potential benefits for patients who have not responded to standard therapies, Allogene Therapeutics said. The ongoing trial is evaluating the safety and efficacy of ALLO-316, supported by Allogene's Dagger technology for enhanced CAR T cell expansion in solid tumors.
The RMAT designation aims to expedite the development and review process of ALLO-316, the company said.
Allogene shares rose 6.5% in recent trading.
Price: 2.86, Change: +0.18, Percent Change: +6.53
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.